Platform

Nutraceuticals

Cosmetics

Standards

Request a Sample Pack

Platform

Nutraceuticals

Cosmetics

Standards

Request a Sample Pack

REFERENCE

KEY FACTS

Verified facts on BOTALYS, its ingredients and the studies behind them, in one place. Figures come from the product pages and the cited publications.

BOTALYS AT A GLANCE

BOTALYS AT A GLANCE

BOTALYS is a Belgian company that grows rare medicinal plants indoors, in a controlled biomimetic environment, and turns them into ingredients for dietary supplements, functional foods and cosmetics.

Company: BOTALYS S.A., Avenue des Artisans 8 box 6, 7822 Ghislenghien, Belgium. US subsidiary: BOTALYS, Inc., Austin, Texas, opened in 2023.
Founded: 2011, by Pierre-Antoine Mariage, under the name Green2Chem.
Technology: biomimetic indoor farming. A vertical farm reproduces each plant’s wild habitat (light, temperature, humidity, atmosphere, substrate) under sterile conditions, without soil, pesticides or chemical inputs.
Facility: a 2,000 m² vertical farm in Belgium dedicated to medicinal plants. Production capacity: 60 tonnes of fresh plants a year, or 3 tonnes of dry material. An extension under way will raise dry capacity to 8 tonnes. Production is vertically integrated, from seed to ingredient.
Quality: ISO 9001 certified; FSSC 22000; EFfCI GMP certification in progress; Halal certification for nutraceutical products; selected products Kosher-certified; DNA identity testing; third-party analyses of bioactive content, pesticides and heavy metals.
Markets: customers in the United States, Europe and Japan.
Management: Pierre-Antoine Mariage (CEO and co-founder), Laurent Pérignon (COO and CFO), Sylvie Defrère (R&D Director), René Cuvelier (Production Director).
Partnerships announced: SEPPIC (co-development and distribution, 2023), L’Oréal and Brightseed (2024), Haleon (strategic partnership, 2025).

INGREDIENTS

INGREDIENTS

Red Ginseng HRG80™: nutraceutical, cognitive health

Whole-root powder of Panax ginseng C.A. Meyer, grown aseptically indoors, steam-cooked and milled to 300 µm. It is not an extract: nothing is taken out and nothing is added back.

Total ginsenosides: 11 to 15% of root weight.
Rare (deglycosylated) ginsenosides: more than 80% of total ginsenosides, about 10% of root weight. For comparison, rare forms make up under 10% of the ginsenosides in white ginseng and 30 to 50% in conventional red ginseng.
Rg3 + Rg5 + Rk1: over 6%. Profile of 23 ginsenosides quantified by UHPLC.
Human studies: five on this exact material, three of them randomized, double-blind and placebo-controlled. The four trials used for claims total about 250 subjects, with no serious adverse events.
Doses tested in humans: 200 mg/day (largest trial, three weeks); about 418 mg/day (attention and EEG trials); 100 mg/day with γ-cyclodextrin (chewable).
Regulatory: EU, not a novel food. US, NDI notification on file.
Formats: capsules, tablets, chewables, sachets and functional beverages.

Black Ginseng Core™: nutraceutical, healthy aging, US market

A two-part ingredient for the SIRT1 and NAD⁺ axis: the same aseptically grown, steam-cooked ginseng as HRG80™, with more than 80% rare ginsenosides, combined with β-nicotinamide mononucleotide (NMN), a precursor of NAD⁺. Patent pending.

Daily dose: 700 mg, made of 200 mg ginseng (about 20 mg rare ginsenosides) and 500 mg NMN.
Evidence: each component has its own published data. The combination has not been tested in a clinical trial.
Regulatory: NMN is lawful in US dietary supplements since FDA’s September 2025 decision. In the EU, NMN is not yet authorised as a novel food, so the formula cannot be sold there as is.

Nativome Ginseng: cosmetic active, cellular longevity

Cold-pressed juice from an aseptically grown Panax ginseng root, with no heat, no solvent and no drying step. The root is pressed within hours of harvest, clarified by sterile filtration that leaves the extracellular vesicles intact, and standardized by HPLC on every batch. Nativome Ginseng is the first ingredient of Nativome by BOTALYS, a range of cosmetic actives that keep the complete native profile of a medicinal plant. Nativome Danshen (Salvia miltiorrhiza) is announced for December 2026.

Form: clarified juice.
Use level: 1 to 3% (3% where the ingredient carries the claim).
Stabilization: glycerin, pentylene glycol, xanthan gum and phytic acid at pH 3.5. No propylene glycol, no preservatives.
Origin: Belgium.
Why it differs from the published ginseng literature: that literature was built almost entirely on dried, steamed or fermented root. Steaming converts the polar ginsenosides into deglycosylated forms and creates Maillard reaction products that fresh root does not contain.

Fjord Rhodiola: Rhodiola rosea

A Nordic Rhodiola rosea cultivar grown in the same indoor process, launched in 2024 after four years of R&D. BOTALYS reports a molecular profile equivalent, on the markers that define maturity, to that of a 15-year-old wild Nordic plant.

STUDIES ON BOTALYS MATERIALS

STUDIES ON BOTALYS MATERIALS

Each result below comes from a study on the BOTALYS ingredient named in the entry, not from the general ginseng literature.

Dormal et al., 2025. HRG80™: stress, mood and planning

Randomized, double-blind, placebo-controlled, parallel groups, UCLouvain. 149 adults aged 18 to 60 with moderate perceived stress (142 analysed), 200 mg/day or placebo for 21 days. Perceived stress (PSS) fell by 4.3 points versus 2.7 with placebo (p = 0.040). PANAS negative affect fell by 2.6 versus 1.1 (p = 0.032). Latency on the CANTAB One Touch Stockings planning task fell by 1,633 ms versus 374 ms (p = 0.036). The decrease in depressive symptom score (BDI-II) did not reach significance (p = 0.073). No serious adverse events, 98% compliance.
Nutrients 2025; 17(6): 955. doi:10.3390/nu17060955. ClinicalTrials.gov NCT06414486.

Mariage et al., 2020. HRG80™: attention under occupational stress

Pilot, randomized, double-blind, placebo-controlled, three-arm crossover. 50 office workers under occupational stress, 14 days per arm: HRG80 about 418 mg/day, white ginseng 382 mg/day, placebo. d2 attention test performance improved versus placebo from the first day of intake on HRG80, while white ginseng did not separate from placebo (p = 0.65). Perceived stress fell from day 5 on HRG80 and from day 12 on white ginseng.
Pharmaceuticals 2020; 13(4): 57. doi:10.3390/ph13040057. ClinicalTrials.gov NCT03947554.

Dimpfel et al., 2021. HRG80™: brain electrical activity in older adults

Randomized, double-blind, placebo-controlled, three-armed crossover over four weeks, 30 adults aged 60 to 75. Quantitative EEG in 17 brain regions after single and repeated intake of HRG80, white ginseng and placebo. Both ginseng preparations changed spectral power versus placebo, with different patterns. HRG80 attenuated delta and theta power during relaxation and produced wider frontal activation during attention tasks.
Pharmaceuticals 2021; 14(3): 182. doi:10.3390/ph14030182.

Hovhannisyan et al., 2022. HRG80™: recovery in elite weightlifters

Open-label, randomized crossover, 20 elite weightlifters, 10 days per phase of intense training, no placebo. Muscle soreness fell versus no treatment with 400 mg/day capsules and with a 100 mg/day γ-cyclodextrin chewable. The capsules also improved push-up performance.
Physical Medicine and Rehabilitation International 2022; 9(3): 1207. ClinicalTrials.gov NCT04932265.

Preclinical studies on HRG80™

Lelong et al., 2024: in rat hippocampal neurons, HRG80 increased neurite length at 0.5 and 1 µg/mL and the synaptic marker PSD-95 at 1 µg/mL. In 18-month-old mice, 50 mg/kg/day for 7 days increased Y-maze novel-arm exploration to a level comparable to young controls. Functional Foods in Health and Disease 2024; 14(8): 574-588. doi:10.31989/ffhd.v14i8.1388.
Dimpfel et al., 2020: one week of oral HRG80 enhanced long-term potentiation in rat hippocampal slices, through NMDA and kainate glutamate receptor transmission. Journal of Alternative, Complementary and Integrative Medicine 2020; 6: 1-9.
Mariage, Defrère and Lelong, 2026: narrative review of the multilevel evidence on HRG80, which reports 1,061 genes modulated by the whole extract and not by isolated ginsenosides. Preprint, not peer reviewed. doi:10.20944/preprints202605.0344.v1.

Nativome Ginseng and BOTALYS ginseng root juice: internal studies

PKDERM, 2026: in adult human dermal fibroblasts (24 h, three independent experiments), Nativome Ginseng increased SIRT1 gene expression in a dose-dependent manner, with relative expression of 1.04, 1.11 and 1.27 at concentrations equivalent to 0.05, 0.1 and 0.2% (p < 0.01 at 0.2%).
StratiCELL, 2024: in human keratinocytes under inflammatory challenge, BOTALYS ginseng root juice reduced IL-6 release by up to 46% at every concentration tested below 0.2%. Confirmation on Nativome Ginseng is in progress.
Both studies are unpublished. Full reports are released to qualified laboratories.

Black Ginseng Core™: evidence on each component

NMN: Yi et al., 2023. Randomized, double-blind, placebo-controlled trial in 80 healthy adults aged 40 to 65. NMN at 300, 600 and 900 mg/day for 60 days raised blood NAD⁺ versus placebo and baseline (p ≤ 0.001), with the highest levels at 600 and 900 mg. GeroScience 2023; 45: 29-43. doi:10.1007/s11357-022-00705-1. ClinicalTrials.gov NCT04823260. Results across NMN trials are not uniform: another 60-day trial at 300 mg/day found no significant rise in blood NAD⁺.
Ginseng: tested alone as HRG80™ at the same 200 mg/day (Dormal et al., 2025, above).
Rare ginsenosides Rg3 and Rg5 increased SIRT1 expression or activity in published cell and animal studies. This has not been measured in humans, nor on this ginseng.

WHAT THE EVIDENCE DOES NOT SHOW

WHAT THE EVIDENCE DOES NOT SHOW

Three of the HRG80™ trials enrolled 50 subjects or fewer, one was open label, and the longest exposure studied is four weeks. Higher doses have not been studied. No trial has tested Black Ginseng Core™ as a combination. The Nativome Ginseng data are in vitro. Permitted health and cosmetic claims depend on the market and on the finished product.

FREQUENTLY ASKED QUESTIONS

FREQUENTLY ASKED QUESTIONS

Is HRG80™ an extract?

No. It is whole ginseng root, steam-cooked and milled. Nothing is extracted and nothing is added back.

What are rare ginsenosides?

Deglycosylated ginsenosides such as Rg3, Rg5 and Rk1. They form when steaming converts the major ginsenosides of fresh root, such as Rb1, Rg1 and Re. In HRG80™ they make up more than 80% of total ginsenosides.

What is the difference between HRG80™ and Nativome Ginseng?

Both come from the same aseptically grown Panax ginseng. HRG80™ is a steam-cooked whole-root powder for supplements, rich in rare ginsenosides. Nativome Ginseng is the fresh root, cold-pressed into a juice for cosmetics, with no heat applied.

How is BOTALYS ginseng grown?

Indoors, in a sealed cleanroom vertical farm in Belgium, without soil, pesticides or chemical inputs, and harvested all year round. Field-grown ginseng usually stays four to six years in the ground under shade covers.

How can I get samples or documentation?

Samples, technical data sheets, the clinical dossier and certificates of analysis are available to qualified brands and formulators through the contact page or at info@botalys.com.
Last updated: November 2026.

KOREAN GINSENG
────────

RHODIOLA ROSEA
────────

SOCIAL
────────

••••••
SUPPORTED BY EU
The project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement N° 859096.

DISCLAIMER
This website is intended to provide general information to industry experts and Health professionals and is not designed for the general public. Since BOTALYS active ingredients are being marketed in multiple countries around the world, it is the responsibility of each of our customers to ensure that the use of the ingredient and any claim made in the labeling or advertising of the ingredient comply with the applicable rules and regulations.

BOTALYS makes the sourcing of rare medicinal plants both possible & sustainable through biomimetic indoor farming, allowing its customers to harness the full potential of biodiversity - all while preserving it.

BOTALYS S.A.
Avenue des Artisans 8 box 6
7822 Ghislenghien, Belgium
TIN: BE 0834.134.177
+32 (0) 68 33 18 08

BOTALYS, Inc.
8205 Mescalero Dr
Austin, TX 78736, USA
+1 (512) 6472578
info@botalys.com

Copyright © BOTALYS SA. All rights reserved.

KOREAN GINSENG
────────

RHODIOLA ROSEA
────────

SOCIAL
────────

••••••
SUPPORTED BY EU
The project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement N° 859096.

DISCLAIMER
This website is intended to provide general information to industry experts and Health professionals and is not designed for the general public. Since BOTALYS active ingredients are being marketed in multiple countries around the world, it is the responsibility of each of our customers to ensure that the use of the ingredient and any claim made in the labeling or advertising of the ingredient comply with the applicable rules and regulations.

BOTALYS makes the sourcing of rare medicinal plants both possible & sustainable through biomimetic indoor farming, allowing its customers to harness the full potential of biodiversity - all while preserving it.

BOTALYS S.A.
Avenue des Artisans 8 box 6
7822 Ghislenghien, Belgium
TIN: BE 0834.134.177
+32 (0) 68 33 18 08

BOTALYS, Inc.
8205 Mescalero Dr
Austin, TX 78736, USA
+1 (512) 6472578
info@botalys.com

Copyright © BOTALYS SA. All rights reserved.